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ABSTRACT 
Objective: Solubility of a drug is an important property that mainly influences the extent of oral bioavailability. Enhancement of oral bioavailability 
of poorly water-soluble drugs is the most challenging aspects of drug development. It is very important to find appropriate formulation approaches 
to improve the aqueous solubility and bioavailability of poorly aqueous soluble drugs. Ezetimibe is a new lipid lowering agent in the management of 
hypercholesterolemia. The drug is water-insoluble, lipophilic, and highly permeable according to the pharmaceutical classification system. 
Therefore, the bioavailability of ezetimibe may be improved by increasing its solubility.  
Methods: In present work solubility of ezetimibe was increased with inclusion complexes by a different technique like physical mixture, co-grinding 
and modified kneading method. The physical properties of the prepared inclusion complex of ezetimibe were characterised by Differential scanning 
calorimetry (DSC), X-ray diffraction spectroscopy (XRD), Fourier transform infra-red spectroscopy (FTIR) and in vitro dissolution studies. 
Results: From the dissolution studies of ezetimibe with HP-β-cyclodextrin(1:1 and 1:2), we conclude that the prepared complexes of ezetimibe with 
HP-β-cyclodextrin (1:2) by modified kneading method showed higher release i.e. 88.35% in 60 min. than in (1:1) 76.75% in 60 min. So, ezetimibe 
with HP-β-cyclodextrin (1:2) inclusion complex was used to formulate tablet by direct compression method.  
Conclusion: From the dissolution data of formulated tablets was observed that drug release was more in tablet dosage form as compared to plain 
ezetimibe and especially formulation in a ratio of 1:2 was found the promising result. Also from one-month stability data shows no significant 
change compared to the initial result.  
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The rate of absorption and bioavailability of poorly water-soluble 
drugs is often controlled by the rate of dissolution of the drug in the 
gastrointestinal tract. Many technological methods of enhancing the 
dissolution characteristics of slightly water soluble drugs are particle 
size reduction, solid dispersion, nanosuspension, supercritical fluid 
technology, cryogenic technology,solid dispersions and inclusion 
complexation [1]. Among the different techniques of solubility 
enhancement, complex inclusion techniques are one of the easiest and 
economical methods of selection which ultimately helps to increase 
the dissolution rate of the drug and its bioavailability. 
Ezetimibe, a poorly water-soluble drug and the oral delivery of the drug 
is frequently associated with low bioavailability. It is used as an anti-
hyperlipidaemia drug in the management of hypercholesterolemia, 
homozygous sitosterolemia (phytosterolemia). After oral administration, 
drug molecule is absorbed and extensively conjugated to a 
pharmacologically active phenolic glucuronide (drug molecule-
glucuronide) [2, 3].  
Cyclodextrins are cyclic oligosaccharides, containing six, seven or eight 
glucopyranose units (α, β or γ respectively) obtained by the enzymatic 
degradation of starch. These are torus shaped molecules with a 
hydrophilic outer surface and lipophilic central cavity, which can 
accommodate a variety of lipophilic drugs [4, 5]. Cyclodextrins are able 
to form inclusion complexes with poorly water-soluble drugs. The 
formation of the inclusion compounds greatly modifies the physical 
and chemical properties of the guest molecule, mostly in terms of 
water solubility. This is the reason why cyclodextrins have attracted 
much interest in many fields, especially pharmaceutical applications: 
because inclusion compounds of cyclodextrins with hydrophobic 
molecules are able to penetrate body tissues, these can be used to 
release biologically active compounds under specific conditions [6, 7]. 
The objective of present study was to prepare inclusion complexes 
of ezetimibe with cyclodextrins by different methods such as 
physical, kneading and co-evaporation, precipitation method and 
increase the solubility of Ezetimibe for improvement of dissolution 
rate and bioavailability of the drug. 
MATERIALS AND METHODS  
Materials  
Ezetimibe was a gift sample from Apollo Life Sciences Pvt. LTD, 
Mumbai India. β-cyclodextrin and H β-cyclodextrin 
was purchased from Roquette India Pvt. LTD, Mumbai. All other 
reagent and chemicals were analytical grade. 
Instruments 
Tablet compression machine: karnavati Mumbai, India 
USP tablet dissolution apparatus II(paddle): Electrolab (TDT-08L), 
Pvt, Ltd, Mumbai,  
Fourier Transform Infra-Red Spectrophotometer: Bruker Alpha, ATR 
model, Mumbai, India. 
UV spectrophotometer: Shimadzu 1800, Japan 
Differential scanning calorimetry: Mettler DSC 1 Star System, Mettler 
Toledo, Switzerland 
X-ray ditractometry: X’pert Pro PANalytical India. 
Stability Chamber: Remi, Mumbai India.  
Methods 
Phase solubility studies 
The phase solubility studies were carried out according to the 
method reported by Higuchi and Connors. Excess amount of 
ezetimibe was added to the screw capped vials containing 60 ml of 
aqueous carrier solution (β-Cyclodextrin and HP-β-Cyclodextrin) at 
various concentrations and placed on an orbital shaker and agitated 
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at room temperature for 72 h. After equilibrium, the solutions were 
carefully filtered through whatman no. 41 filter paper and after 
appropriate dilution; solutions were analysed at 231 nm by using 
UV-visible spectrophotometry [8]. 
Preparation of inclusion complexes of ezetimibe with β-
cyclodextrin and HP-β-cyclodextrin 
Physical mixture  
The physical mixtures of ezetimibe with cyclodextrin were prepared 
by simple mixing using a spatula. This resulting mixture was sieved 
through a 80 mesh screen [10, 12]. The composition of the physical 
mixture is given in table 1.  
Co-grinding complex 
The required amount of ezetimibe and carriers were taken in a mortar 
pestle and grind for 45 min until a homogeneous complex was obtained. 
This resulting complex was sieved through an 85 mesh screen. The 
powder was stored in a screw cap container at room temperature [10, 
12]. The composition of co-grinding is given in table 1.  
Modified kneading method 
Inclusion complexes were prepared by modified kneading 
technique. Ezetimibe and polymer were dissolved in ethanol and 
water in a proportion of 50:50, then the mixture were kneaded for 
45 min and the slurry were obtained, the flask kept on the water 
bath till ethanol get evaporated and then resultant slurry were kept 
in deep freezer for 24 h and then freeze complex were dried by 
freeze dryer. The operating parameters like-40 °C, and 4 kg/test 
cycle pressure to be maintained [10, 12]. The composition of 
modified kneading method is given in table 1. 
 
Table 1: Composition for physical mixture/co-grinding/ 







1 Ezetimibe: β-Cyclodextrin 1:1 
2 Ezetimibe: β-Cyclodextrin 1:2 
3 Ezetimibe: HP-β-Cyclodextrin 1:1 
4 Ezetimibe: HP-β-Cyclodextrin 1:2 
  
Analysis of drug content 
The content of ezetimibe in each physical mixture, co-grinding and 
modified kneading method of inclusion complexes was determined using 
by UV spectroscopy. Accurately weighed physical mixture, co-grinding 
and modified kneading method inclusion complexes equivalent to 10 mg 
of ezetimibe was transferred to 100 ml volumetric flask containing 40 ml 
of ethanol and dissolved. The volume was made up to 100 ml with water. 
The solution was filtered through 0.45 µm membrane filter paper. One 
ml of this solution was diluted 10 times with the same solvent and the 
absorbance was measured at 231mn [12, 14]. 
Characterization of inclusion complexes 
Fourier transform infra-red spectroscopy (FTIR)  
The IR spectrum of ezetimibe, β-cyclodextrin, HP-β-cyclodextrin and 
the physical mixture, co-grinding complex and modified kneading 
complex with β-cyclodextrin and HP-β-cyclodextrin were recorded 
in the stretching frequency range of 450 to 4000 cm-1 [14]. The 
samples were evaluated by ATR model.  
Differential scanning calorimetry (DSC) 
The DSC thermograms of ezetimibe, β-cyclodextrin, HP-β-
cyclodextrin and the physical mixture, co-grinding complex and 
modified kneading complex with β-cyclodextrin and HP-β-
cyclodextrin were recorded. The samples were separately sealed in 
aluminium cells and set in Perkinelmer (pyris 1) DSC. The thermal 
analysis was performed in a nitrogen atmosphere over a 
temperature range of 50 °C to 250 °C [14]. 
X-ray diffraction spectroscopy 
The X-ray diffraction pattern of ezetimibe, β-cyclodextrin, HP-β-
cyclodextrin and the physical mixture, co-grinding complex and 
modified kneading complex with β-cyclodextrin and HP-β-
cyclodextrin were recorded from 5 to 100 °C at an angle 2θ using 
diffractometer system [14]. 
Dissolution rate studies  
Dissolution studies were performed separately in 900 ml water with 
0.25% sodium lauryl sulphate maintained at 37 °±0.5 °C using USP 
XXII type II dissolution test apparatus at a speed of 50 rpm. The 
physical mixture or inclusion complexes, equivalent to 10 mg of 
ezetimibe was taken for dissolution studies. Samples of 10 ml were 
withdrawn at regular intervals and replaced the same with fresh 
dissolution medium. The samples were estimated for the amount of 
dissolved by measuring their absorbance at 231 nm [12, 14]. The 
amount of released was calculated and plotted against time and 
compared with the pure drug. (fig. 11 and 12). 
Preparation of tablets of inclusion complexes 
The optimised modified kneading complex was formulated in tablets 
containing the equivalent to 10 mg of ezetimibe inclusion complexes 
were prepared by direct compression. The blend was compressed on 
a 10 station rotary machine using round shaped, concave punches 
[22, 23]. The composition of tablet is given in table 2.  
 
Table 2: Composition of tablet formulation 
Ingredients Quantity (mg) 
Modified kneading complex (1:2 HP-β-
Cyclodextrin) 
76 
Microcrystalline cellulose 62 
Magnesium stearate 2 
Total 140 
 
Evaluation of powder blend 
The powder blend was evaluated for flow properties. Different tests 
that were carried out are bulk density, tapped density, 
compressibility index, and hausner ratio. 
Evaluation of tablets  
The hardness of the tablets was evaluated using the pfizer hardness 
tester. The friability of tablets for each batch was determined using 
automated USP roche friabilator. The tablets were subjected to tests 
like the uniformity of drug content, and variation weight tests single 
dose preparation as per US Pharmacopeia (USP) [22, 23]. 
In vitro dissolution study  
Dissolution studies were performed separately in 900 ml of pH 1.2, 
pH 6.8 and water with 0.25 % sodium lauryl sulphate maintained at 
37 °±0.5 °C using USP XXII type II dissolution test apparatus at a 
speed of 50 rpm. The sample (10 ml) was withdrawn at regular time 
intervals and replaced the same with fresh dissolution medium. The 
samples were estimated for amount of dissolved by measuring their 
absorbance at 231 nm [22, 23]. The amount of released was 
calculated and plotted against time (fig. 11 and 12) 
Stability studies  
The optimised formulation was kept for short-term stability study. 
The conditions for stability were 30 °C±2 °C room temperature and 
relative humidity of 65% RH±5% RH. All tablets were suitably 
packed in a group of 10 in aluminium foil. [15] At the end of one 
month the sealed tablets were opened and evaluated. 
Statistical analysis 
All analyses of data were performed with a statistical software 
package (SPSS 13, USA). The results are expressed as means and 
standard deviations. Comparative statistical studies on the inclusion 
complex and dissolution rate were performed by ANOVA.  
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RESULTS AND DISCUSSION 
Phase solubility studies 
The phase solubility studies were performed to determine 
stoichiometric proportions of ezetimibe and carrier’s β-cyclodextrin 
and HP-β-cyclodextrin. The effects of polymers concentration at 
room temperature on solubility are shown in (fig. 1).  
 
 
Fig. 1: Concentration of (-♦-) β-cyclodextrin and (-■-) HP-β-
cyclodextrin carriers on solubility of ezetimibe[mean±SD, n= 3]. 
Error bars were omitted for clear presentation 
 
The plot of drug solubility against polymer concentrations at room 
temperature indicated a linear relationship between drug and 
polymer solution. The ezetimibe and carriers β-cyclodextrin and HP-
β-cyclodextrin is r² = 0.946, r² = 0.968 respectively. Which indicated 
that 1:1 (Ezetimibe: β-CD) and (Ezetimibe: HP-β-CD) inclusion 
complex formed in solution. The value of stability constant (Ks) for 
complexes (Ezetimibe: β-CD) and (Ezetimibe: HP-β-CD) at 37 °±0.5 
°C, were 241.59 M-1 and 926.99 M-1 respectively. It is reported that 
cyclodextrin-drug complexes with the values of Ks in the range of 
200 to 5000 M-1 show improved dissolution properties. 
Evaluation of complexes 
Analysis of drug content 
The percentage of drug content of the physical mixture, co-grinding 
complex and modified kneading complex are shown in table 3. 
Fourier transform infra-red spectroscopy (FTIR) 
Fourier transform infrared spectroscopy has been used to assess the 
interaction between the carrier and drug molecule. The FTIR 
spectrum of ezetimibe, HP-β-cyclodextrin and inclusion complex 
prepared by attenuated total refluctance. FTIR spectra are shown in 
(fig.2,3,4). In IR spectra of ezetemibe the O-H stretching in alcohols 
occurs at 3239.72 cm-1, the C-H stretching in alkanes at 2909.49 cm-
1, the C= O stretching in carboxylic acids occurs at 1714.12 cm-1, the 
C-N stretching in amine occurs at 1217.03 and the C-F stretching in 
alkyl halides occurs at occurs at 1066.65 cm-1, the C=C stretching in 
benzene ring occurs at 1508.93. In IR spectra of HP-β-cyclodextrin 
the O-H Stretching in free hydroxyl occurs at 3401.06 cm-1, the C-H 
Strecthing in Alkanes occurs at 2929.89 cm-1, the C=O strecting in 
ethers occurs at 1653 cm-1, the C-O strecting in ethers occurs at 
1032.36 cm-1. In IR spectra of inclusion complex the O-H stretching 
in alcohols occurs at 3287.40 cm-1, the C=O stretching in carboxylic 
acids occurs at 1729.80 cm-1, the C-C stretching in aromatics occurs 
at 1508.02 cm-1, the C-H stretching in aromatic occurs at 1397.07 
cm-1, the C-F stretching in alkyl halides 1027.29 cm-1. 
  
Table 3: Results of drug content with β-CD and HP-β-CD 
Methods Ratio Drug content 
Ezetimibe: β-CD Ezetimibe: HP-β-CD 
Physical Mixture 1:1 96.10±0.06 98.00±0.12 
1:2 97.35±0.15 98.50±0.05 
Co-grinding Complex 1:1 95.17±0.12 97.41±0.10 
1:2 96.15±0.08 97.39±0.04 
Modified Kneading Method 1:1 97.80±0.05 98.88±0.08 
1:2 98.55±0.08 99.15±0.07 
[mean±SD, n= 3] 
 
 
Fig. 2: FTIR spectrum of ezetimibe 
 
 
Fig. 3: FTIR spectrum of HP-β-cyclodextrin 
 
Fig. 4: FTIR spectrum of the inclusion complex prepared with 
HP-β-CD by modified kneading method (1:2) 
 
Differential scanning calorimetry (DSC) 
The DSC thermogram of ezetimibe, HP-β-cyclodextrin and its 
complex prepared by modified kneading method as shown in (fig. 5, 
6, 7) respectively. The DSC curve of ezetimibe exhibited a sharp 
endothermic peak at 163.66 °C corresponding to its melting point. 
The DSC curve of HP-β-cyclodextrin showed a broad endothermic 
peak at 120.35 °C. The heat content of Ezetimibe was found to be-
178.32 mJ and for HP-β-cyclodextrin it was-748.21 mJ respectively. 
The melting point and heat content of modified kneading complex of 
ezetimibe with HP-β-cyclodextrin in the ratio (1:2) were found to be 
160.13 °C and-3.37 mJ.  
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Fig. 5: DSC thermogram of ezetimibe 
 
 
Fig. 6: DSC thermogram of HP-β-cyclodextrin 
 
 
Fig. 7: DSC thermogram of the inclusion complex prepared with 
HP-β-CD by modified kneading method (1:2) 
 
X-ray diffraction (XRD) 
Powder X-ray diffraction spectroscopy has been used to assess the 
degree of crystallinity of the given sample. XRD patterns are shown 
in (fig. 8, 9, and 10). The X-ray diffraction pattern of ezetimibe 
exhibited sharp, highly intense and less diffused peaks indicating the 
crystalline nature of ezetimibe. HP-β-cyclodextrin showed diffused 
peaks because of its amorphous nature. The X-ray diffraction pattern 
of modified kneading method of ezetimibe with HP-β-cyclodextrin 
showed less intense and highly diffused peaks.  
 
 
Fig. 8: XRD of ezetimibe 
 
 
Fig. 9: XRD of HP-β-cyclodextrin 
 
 
Fig. 10: XRD of the inclusion complex prepared with HP-β-CD by 
modified kneading method (1:2) 
 
In vitro dissolution studies of modified kneading method  
In order to study the release profile of ezetimibe and modified 
kneading complex was subjected to dissolution studies in (a) 
Distilled water, (b) pH 1.2 and (c) pH 6.8. The results are as shown in 
(fig. 11, 12) 
  
 
Fig. 11: Dissolution profile of (-♦-) ezetimibe, modified kneading complex of ezetimibe with β-CD 1:1 (-■-) and modified kneading complex 
of ezetimibe with β-CD 1:2 (-▲-) [mean±SD, n= 3]. Error bars were omitted for clear presentation 
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Fig. 12: Dissolution profile of (-♦-) ezetimibe, modified kneading complex of ezetimibe with HPβ-CD 1:1 (-■-) and modified kneading 
complex of ezetimibe with HPβ-CD 1:2 (-▲-) [mean±SD, n= 3]. Error bars were omitted for clear presentation 
 
In order to investigate the drug release from the prepared inclusion 
complex, in vitro dissolution study carried out in distilled water, pH 1.2 
and pH 6.8. The inclusion complex prepared with HP-β-cyclodextrin by 
modified kneading method (1:2) showed better drug release as 
compared to inclusion complex prepared with β-CD. The drug release 
rate of modified kneading method with HP-β-CD (1:2) was 82.58±0.28 in 
30 min., 85.87±1.59 in 30 min and 88.45±0.90 in 45 min. in distilled 
water, pH 1.2 and pH 6.8 which is as shown in fig 11and 12.  
Respectively. From the results of dissolution studies, the modified 
kneading method (1:2) prepared by using HP-β-cyclodextrin was 
selected for tablet formulation. 
Pre-compression evaluation of tablet blend 
The results of pre-compression evaluation of tablet blend are given 
in table 4. 
Evaluation of tablet 
Hardness, % friability, weight variation and drug content of tablet 
are given in table 5. 
 
Table 4: Evaluation of inclusion complex tablet blend 
Parameter Result 
Angle of Repose 25.78±0.11 
Bulk density (g/ml) 0.43±0.05 
Tapped density (g/ml) 0.46±0.02 
% compressibility 12.76±0.35 
Hausner ratio 1.06±0.04 
 [mean±SD, n= 3] 
 
 Table 5: Post compression evaluation of formulated tablet 
Parameters Results 
Weight Uniformity (mg) 140±0.15 
Friability (%) 0.5±0.03 
Thickness (mm) 3.5±0.24 
Hardness (Kg/cm2) 3.8±0.08 
Content uniformity 98.10±0.15 
Disintegration time (min) 10.5±0.45 
 [mean±SD, n= 3] 
Dissolution study of formulated tablet  
The formulated tablets were subjected to dissolution study in 
distilled water, pH 1.2 and pH 6.8 results were shown in (fig. 13) 
 
 
Fig. 13: In vitro drug release of ezetimibe from tablet 
formulation in (-♦-) distilled water, (-■-) pH 1.2 and (-▲-) pH 
6.8[mean±SD, n= 3]. Error bars were omitted for clear 
presentation 
 
From the fig. 13, it was observed that the drug release rate of 
formulation in distilled water, pH 1.2 and pH 6.8 was 65.20% in 
30 min. and 85.13% in 45 min. and 88.25 % in 30 min. 
respectively. 
Stability study 
At the end of one month, the formulation was tested for different 
parameters such as hardness, friability, disintegration time and 
dissolution. The results observed are reported in table 6. 
 
Table 6: Results of stability study 
Parameters Result 
Initial After stability study 
Hardness (kg/cm2) 3.8±0.10 3.8±0.07 
Friability (%) 0.5±0.39 0.5±0.45 
Disintegration time 10.5±0.10 10.5±0.32 
Dissolution 65.20% in Water 
85.13% in pH 1.2 
88.25%in pH 6.8 
64.34% in Water 
83.25% in pH 1.2 
87.12 %in pH 6.8 
Drug content 98.10±0.15 97.05±.017 
[mean±SD, n= 3] 
 
DISCUSSION 
The solubility curve was classified as the AL type according to 
Higuchi and Connors shown that the apparent solubility of ezetimibe 
increases linearly as a function of HP β-cyclodextrin over the entire 
concentration range and was the characteristic of AL type of curve 
[8], which suggests that water soluble complex was formed in 
solution. Percentage drug content of the complexes are shown in the 
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table and found within the range 96.10% to 99%. The maximum % 
drug content was found to be 99.15 % in modified kneading method. 
The FTIR spectra of ezetimibe and HP β-cyclodextrin inclusion 
complexes showed the absence of the spectra of pure drug which 
indicates entrapment of drug into the cavity and confirms the 
complex formation. In DSC thermogram of modified kneading 
complex of ezetimibe with HP β-cyclodextrin in the ratio 1:2, the 
endothermic peak was reduced as compared to the ezetimibe. From 
the results of heat content, it can conclude that lower heat absorbed 
in the melting process of ezetimibe indicated increased solubility 
from modified kneading complex with HP β-cyclodextrin. When 
complexation of drug and HP β-cyclodextrin/β-cyclodextrin is 
formed, the overall number of crystalline structures is increased. 
The final product sample shows less number as well as less intensity 
of XRD peaks. This shows that overall crystallinity of complexes was 
decreased and due to more amorphous nature the solubility was 
increased [12, 14]. From the result, it concludes that the inclusion 
complex prepared by modified kneading method of ezetimibe and 
HP β-cyclodextrin showed a reduction in peak intensity as compared 
to ezetimibe indicating the formation of an inclusion complex. The 
dissolution performance of inclusion complex by kneading method 
was increased as compared to pure ezetimibe, physical mixture and 
co-grinding complex in water, pH 1.2 and pH 6.8 in particular time 
course. This may be attributed to improved wettability of drug 
particles significant reduction particle size during formation of 
inclusion complex and intrinsically higher rate of dissolution of the 
selected soluble polymer, which could pull insoluble but finely 
mixed drug into the bulk of dissolution medium. 
In pre-compression evaluation of tablet, the value of the angle of repose 
was found to be below 30 °C which indicates good flow property. The 
bulk density and tapped density value was found to be less than one. 
Similarly, the % compressibility value for all batches was less than 16% 
which also indicate that all batches of tablet blend have good flow 
property. Hardness, friability, weight variation, thickness, the 
disintegration time of tablet formulation were within acceptable limits 
and exhibited maximum release in distilled water and in phosphate 
buffer at pH 6.8. Hence formulation selected for stability study showed 
no significant changes in post compression evaluation parameter. 
CONCLUSION  
The present investigation revealed that ezetimibe can form an 
inclusion complex with β-cyclodextrin and HP-β-cyclodextrin in the 
solid state. The stoichiometry of complex formation is in 1:1 molar 
ratio with better stability constant. From these results, it can be 
assumed that the formation of the inclusion complex of ezetimibe 
with HP-β-cyclodextrin can increase the aqueous solubility of 
ezetimibe more than with β-cyclodextrin. The improved dissolution 
rate may be due to increasing insolubility, brought about by 
complexation, amorphizing power of HP-β-CD and mechanical 
treatment. From this evidence, it can be concluded that the aqueous 
solubility and dissolution rate of Ezetimibe can be significantly 
increased by forming an inclusion complex with HP-β-cyclodextrin. 
Further, inclusion complexes prepared by modified kneading 
method is found to be superior with respect to enhancement in 
aqueous solubility than those obtained by the physical mixture and 
co-grinding complex. From the dissolution data of formulated tablets 
was observed that drug release was more in tablet dosage form as 
compared to plain Ezetimibe and especially formulation in a ratio of 
1:2 was found the promising result. Also from one-month stability 
data shows no significant change compared to the initial result. 
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